FDA Clearance Tracker · P230032-S003
AvertD and AvertD Buccal Sample Collection Kit
Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jan 29, 2026
Approved
Time to decision
30 days
Received Dec 30, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230032-S003
- Device name
- AvertD and AvertD Buccal Sample Collection Kit
- Applicant
- AutoGenomics, Inc.
- Applicant location
- Carlsbad, CA
- Received
- Dec 30, 2025
- Decided
- Jan 29, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P230032
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of changes to the clinical protocol for the post-approval study (PAS) for P230032.
Source documents
Other decisions for AutoGenomics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- AvertD and AvertD Buccal Sample Collection KitBreakthroughPMA
P230032 · Decided Dec 19, 2023 · 85 days after receipt
Device type: Opioid use disorder genetic risk variant detection system and collection kit (QZH) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.